CytoMed Therapeutics Ltd (GDTC)

NASDAQ
Currency in USD
2.340
+0.100(+4.46%)
Real-time Data·
GDTC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 14 days
Fair Value
Day's Range
2.3402.340
52 wk Range
1.2004.050
Key Statistics
Edit
Prev. Close
2.27
Open
2.34
Day's Range
2.34-2.34
52 wk Range
1.2-4.05
Volume
251
Average Volume (3m)
18.41K
1-Year Change
7.08%
Book Value / Share
0.57
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GDTC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

CytoMed Therapeutics Ltd Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Compare GDTC to Peers and Sector

Metrics to compare
GDTC
Peers
Sector
Relationship
P/E Ratio
−13.9x−0.6x−0.5x
PEG Ratio
−0.31−0.010.00
Price/Book
3.9x2.6x2.6x
Price / LTM Sales
69.6x7.6x2.9x
Upside (Analyst Target)
117.4%511.4%50.4%
Fair Value Upside
Unlock−5.7%9.1%Unlock

Earnings

Latest Release
May 05, 2025
EPS / Forecast
-- / -0.04
Revenue / Forecast
-- / 130.00K
EPS Revisions
Last 90 days

FAQ

What Is the CytoMed Therapeutics (GDTC) Stock Price Today?

The CytoMed Therapeutics stock price today is 2.34

What Stock Exchange Does CytoMed Therapeutics Trade On?

CytoMed Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for CytoMed Therapeutics?

The stock symbol for CytoMed Therapeutics is "GDTC."

What Is the CytoMed Therapeutics Market Cap?

As of today, CytoMed Therapeutics market cap is 26.20M.

What Is CytoMed Therapeutics's Earnings Per Share (TTM)?

The CytoMed Therapeutics EPS (TTM) is -0.22.

When Is the Next CytoMed Therapeutics Earnings Date?

CytoMed Therapeutics will release its next earnings report on 27 May 2025.

From a Technical Analysis Perspective, Is GDTC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.